--- title: "Ascentage Pharma Group International (6855) news: IPO" url: "https://aibio.space/companies/ascentage-pharma-international/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "6855 IPO news: Ascentage Pharma prices U.S. IPO of 7,325,000 ADSs at US$17.25. Ascentage Pharma Group International (HKEX: 6855), China." --- 6855 Ascentage Pharma Group International HKEX · China # Ascentage Pharma Group International (6855) news 6855 IPO news Financings · 2025-01-24 ## [Ascentage Pharma prices U.S. IPO of 7,325,000 ADSs at US$17.25](https://aibio.space/news/ascentage-pharma-prices-u-s-ipo-7-325-000-adss-us-17-25/) The ADSs are approved to list on Nasdaq under AAPG, with J.P. Morgan and Citigroup as the underwriters named on the cover. The company's ordinary shares have traded in Hong Kong under code 6855 since October 28, 2019. ## Latest Ascentage Pharma Group International news 1. 2024-12-27 Financings [Ascentage Pharma files for U.S. IPO of ADSs, plans Nasdaq listing as AAPG](https://aibio.space/news/ascentage-pharma-files-u-s-ipo-adss-plans-nasdaq-listing-aapg/) The Cayman Islands company's shares have traded in Hong Kong under stock code 6855 since October 28, 2019. The ADS count and price are blank, and J.P. Morgan and Citigroup are named on the cover. ## Ascentage Pharma Group International at a glance - **Ticker**: 6855 - **Listing**: HKEX - **Country**: China - **Cash, Dec 31, 2024**: $122.4 million ### Related companies - [Gansu Longshenrongfa Pharmaceutical Industry Co.](https://aibio.space/companies/gansu-longshenrongfa-pharmaceutical-industry/) SZSE: 300534 - [Hainan Shuangcheng Pharmaceuticals Co.](https://aibio.space/companies/hainan-shuangcheng-pharmaceuticals/) SZSE: 002693 - [BGM Group](https://aibio.space/companies/bgm/) NASDAQ: BGM - [Jiangxi Synergy Pharmaceutical Co.](https://aibio.space/companies/jiangxi-synergy-pharmaceutical/) SZSE: 300636 - [Zhejiang Ausun Pharmaceutical Co.](https://aibio.space/companies/zhejiang-ausun-pharmaceutical/) SSE: 603229 - [Qingdao Baheal Medical](https://aibio.space/companies/qingdao-baheal-medical/) SZSE: 301015 - [Harbin Gloria Pharmaceuticals Co.](https://aibio.space/companies/harbin-gloria-pharmaceuticals/) SZSE: 002437 - [Zhejiang Xianju Pharmaceutical Co.](https://aibio.space/companies/zhejiang-xianju-pharmaceutical/) SZSE: 002332 ### Also on HKEX - [Consun Pharmaceutical Group](https://aibio.space/companies/consun-pharmaceutical/) 1681 - [PegBio Co.](https://aibio.space/companies/pegbio/) 2565 - [Shenzhen Neptunus Interlong Bio-Technique Co.](https://aibio.space/companies/shenzhen-neptunus-interlong-bio-technique/) 8329 - [Qyuns Therapeutics Co.](https://aibio.space/companies/qyuns-therapeutics/) 2509 - [Hua Medicine](https://aibio.space/companies/hua-medicine/) 2552 - [Alphamab Oncology](https://aibio.space/companies/alphamab-oncology/) 9966 ## Ascentage Pharma Group International annual financials | Line | FY2024 | |---|---| | Revenue | [$134.3 million](https://www.sec.gov/Archives/edgar/data/2023311/000121390025032599/) | | Research and development | [$129.8 million](https://www.sec.gov/Archives/edgar/data/2023311/000121390025032599/) | | Net income (loss) | [-$55.6 million](https://www.sec.gov/Archives/edgar/data/2023311/000121390025032599/) | | Cash from operations | [-$15.3 million](https://www.sec.gov/Archives/edgar/data/2023311/000121390025032599/) | | Cash and equivalents | [$122.4 million](https://www.sec.gov/Archives/edgar/data/2023311/000121390025032599/) | Latest balance sheet, Dec 31, 2024 (20-F): cash and equivalents $122.4 million. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Ascentage Pharma Group International When did Ascentage Pharma Group International go public? Our latest story on this, dated Jan 24, 2025: "Ascentage Pharma prices U.S. IPO of 7,325,000 ADSs at US$17.25". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/ascentage-pharma-prices-u-s-ipo-7-325-000-adss-us-17-25/). What is the ticker symbol of Ascentage Pharma Group International? Ascentage Pharma Group International trades under the ticker 6855 on HKEX. Where is Ascentage Pharma Group International listed? Ascentage Pharma Group International is listed on HKEX. Our directory also records these other listings: NASDAQ:AAPG; OTC:ASPHF. What is the SEC CIK of Ascentage Pharma Group International? The SEC Central Index Key (CIK) for Ascentage Pharma Group International is 2023311. Its filings are on SEC EDGAR. How many shares does Ascentage Pharma Group International have outstanding? 373,322,192 shares as of 2026-04-01, per the cover page of its 20-F filed 2026-04-29. Which country or territory is Ascentage Pharma Group International listed under? Our directory records Ascentage Pharma Group International under China. What does Ascentage Pharma Group International do? Our directory classifies Ascentage Pharma Group International as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline. What is the ISIN of Ascentage Pharma Group International? The ISIN recorded for Ascentage Pharma Group International is KYG0519B1023. Does aibio.space cover Ascentage Pharma Group International? aibio.space lists Ascentage Pharma Group International among 2,820 public biotech companies and publishes its news here as stories appear. Where is Ascentage Pharma Group International incorporated? SEC records list its state or country of incorporation as E9. What was Ascentage Pharma Group International's revenue last year? $134.3 million for the fiscal year ended Dec 31, 2024, as reported to the SEC. Is Ascentage Pharma Group International profitable? Ascentage Pharma Group International reported a net loss of $55.6 million for the fiscal year ended Dec 31, 2024, and used $15.3 million of cash in operations, per its annual report to the SEC. How much does Ascentage Pharma Group International spend on research and development? $129.8 million in the fiscal year ended Dec 31, 2024, per its annual report. How much cash does Ascentage Pharma Group International have? $122.4 million in cash at Dec 31, 2024, per its 20-F. What is the latest Ascentage Pharma Group International (6855) stock news? Our latest story on Ascentage Pharma Group International, dated Jan 24, 2025: "Ascentage Pharma prices U.S. IPO of 7,325,000 ADSs at US$17.25". The ADSs are approved to list on Nasdaq under AAPG, with J.P. Morgan and Citigroup as the underwriters named on the cover. The company's ordinary shares have traded in Hong Kong under code 6855 since October 28, 2019. [Source](https://aibio.space/news/ascentage-pharma-prices-u-s-ipo-7-325-000-adss-us-17-25/). ## Investor discussion: Ascentage Pharma Group International Members talk about Ascentage Pharma Group International (6855). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Ascentage Pharma Group International, newest first. Each line links the filing it comes from. 1. 2026-09-17 Financings Reported a financing. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/2023311/000121390026100763/ea030579601ex99-1.htm) 2. 2026-07-20 Financings Reported a financing. SEC Form F-3ASR. [Source](https://www.sec.gov/Archives/edgar/data/2023311/000121390026079362/ea0298372-f3asr_ascentage.htm) 3. 2026-04-28 Financings Share or debt issue: PROPOSED RE-ELECTION OF RETIRING DIRECTORS; PROPOSED GRANTING OF GENERAL MANDATES TO ISSUE SHARES AND REPURCHASE SHARES; PROPOSED AMENDMENTS TO THE MEMORANDUM AND ARTICLES OF ASSOCIATION AND PROPOSED ADOPTION OF THE THIRD AMENDED AND RESTATED MEMORANDUM AND ARTICLES OF ASSOCIATION; AND NOTICE OF ANNUAL GENERAL MEETING. [Source](https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0429/2026042900023.pdf) 4. 2025-07-25 Financings Share or debt issue: CLOSING OF PLACING OF EXISTING SHARES AND TOP-UP SUBSCRIPTION OF NEW SHARES UNDER GENERAL MANDATE. [Source](https://www1.hkexnews.hk/listedco/listconews/sehk/2025/0725/2025072501481.pdf) 5. 2025-07-15 Financings Reported a financing. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/2023311/000121390025063825/ea024893701ex99-1_ascentage.htm) 6. 2025-07-14 Financings Share or debt issue: PLACING OF EXISTING SHARES AND TOP-UP SUBSCRIPTION OF NEW SHARES UNDER GENERAL MANDATE. [Source](https://www1.hkexnews.hk/listedco/listconews/sehk/2025/0715/2025071500005.pdf) 7. 2025-04-17 Financings Reported a financing. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/2023311/000121390025032670/ea0238587ex99-1_ascentage.htm) 8. 2025-04-16 Financings Share or debt issue: PROPOSED RE-ELECTION OF RETIRING DIRECTORS, PROPOSED GRANTING OF GENERAL MANDATES TO ISSUE SHARES AND REPURCHASE SHARES AND NOTICE OF ANNUAL GENERAL MEETING. [Source](https://www1.hkexnews.hk/listedco/listconews/sehk/2025/0416/2025041601737.pdf) 9. 2025-02-13 Financings Share or debt issue: CLOSING OF THE PARTIAL EXERCISE OF THE OVER-ALLOTMENT OPTION IN RELATION TO THE OFFERING OF AMERICAN DEPOSITARY SHARES. [Source](https://www1.hkexnews.hk/listedco/listconews/sehk/2025/0214/2025021400005.pdf) 10. 2025-02-11 Financings Reported a financing. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/2023311/000117184325000725/exh_991.htm) 11. 2025-02-07 Financings Share or debt issue: PARTIAL EXERCISE OF THE OVER-ALLOTMENT OPTION IN RELATION TO THE OFFERING OF AMERICAN DEPOSITARY SHARES. [Source](https://www1.hkexnews.hk/listedco/listconews/sehk/2025/0207/2025020700899.pdf) 12. 2025-02-02 Financings Share or debt issue: CLOSING OF THE OFFERING OF AMERICAN DEPOSITARY SHARES. [Source](https://www1.hkexnews.hk/listedco/listconews/sehk/2025/0202/2025020200021.pdf) 13. 2025-01-24 Financings Filed a final prospectus for a securities offering. SEC Form 424B4. [Source](https://www.sec.gov/Archives/edgar/data/2023311/000110465925006029/tm2415654-19_424b4.htm) 14. 2025-01-24 Financings Share or debt issue: OFFERING OF AMERICAN DEPOSITARY SHARES AND ISSUANCE OF NEW ORDINARY SHARES UNDER THE GENERAL MANDATE. [Source](https://www1.hkexnews.hk/listedco/listconews/sehk/2025/0124/2025012400185.pdf) 15. 2024-12-27 Financings Filed a registration statement for a share offering. SEC Form F-1. [Source](https://www.sec.gov/Archives/edgar/data/2023311/000110465924132177/tm2415654-12_f1.htm) ## Press releases Headlines of Ascentage Pharma Group International's own announcements, newest first. Each opens the full release on the newswire that carried it. 1. 2026-10-22 HKEXnews [VOLUNTARY ANNOUNCEMENT - PURCHASE OF SHARES BY THE TRUSTEE FOR THE PURPOSE OF THE 2022 RSU SCHEME](https://www1.hkexnews.hk/listedco/listconews/sehk/2026/1022/2026102201402.pdf) 2. 2026-10-20 HKEXnews [VOLUNTARY ANNOUNCEMENT - ASCENTAGE PHARMA'S LISAFTOCLAX GRANTED BREAKTHROUGH THERAPY DESIGNATION IN CHINA FOR TREATMENT-NAIVE CLL/SLL](https://www1.hkexnews.hk/listedco/listconews/sehk/2026/1021/2026102100017.pdf) 3. 2026-10-15 HKEXnews [VOLUNTARY ANNOUNCEMENT - PURCHASE OF SHARES BY THE TRUSTEE FOR THE PURPOSE OF THE 2022 RSU SCHEME](https://www1.hkexnews.hk/listedco/listconews/sehk/2026/1015/2026101501164.pdf) 4. 2026-09-28 HKEXnews [VOLUNTARY ANNOUNCEMENT - ACQUISITION OF SHARES BY THE CHAIRMAN AND EXECUTIVE DIRECTOR](https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0928/2026092802053.pdf) 5. 2026-09-17 HKEXnews [VOLUNTARY ANNOUNCEMENT - PURCHASE OF SHARES BY THE TRUSTEE FOR THE PURPOSE OF THE 2022 RSU SCHEME](https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0917/2026091701633.pdf) 6. 2026-08-19 HKEXnews [ANNOUNCEMENT OF UNAUDITED INTERIM RESULTS FOR THE SIX MONTHS ENDED JUNE 30, 2026](https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0820/2026082000029.pdf) 7. 2026-08-02 HKEXnews [VOLUNTARY ANNOUNCEMENT - Ascentage Pharma Appoints Dr. Faical Miyara as Chief Business Officer and Jim Ziegler as Chief Commercial Officer](https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0803/2026080300017.pdf) 8. 2026-07-19 HKEXnews [VOLUNTARY ANNOUNCEMENT AND OVERSEAS REGULATORY ANNOUNCEMENT - PROPOSED AT-THE-MARKET OFFERING PROGRAM PURSUANT TO A REGISTRATION STATEMENT ON FORM F-3 FILED WITH THE U.S. SECURITIES AND EXCHANGE COMMISSION AND APPLICATION FOR WAIVERS FROM THE LISTING RULES](https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0719/2026071900105.pdf) 9. 2026-07-13 HKEXnews [UPDATE ON THE FURTHER GRANT OF AWARDS UNDER THE 2021 RSU SCHEME AND THE 2022 RSU SCHEME; AND FURTHER GRANT OF OPTIONS UNDER THE POST IPO SHARE OPTION SCHEME](https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0713/2026071300021.pdf) 10. 2026-06-29 HKEXnews [FURTHER GRANT OF AWARDS UNDER THE 2021 RSU SCHEME AND THE 2022 RSU SCHEME; AND FURTHER GRANT OF OPTIONS UNDER THE POST IPO SHARE OPTION SCHEME](https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0630/2026063000266.pdf) 11. 2026-06-14 HKEXnews [VOLUNTARY ANNOUNCEMENT - ASCENTAGE PHARMA RELEASES MULTIPLE CLINICAL UPDATES AT EHA2026 CONGRESS](https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0615/2026061500077.pdf) 12. 2026-06-11 HKEXnews [VOLUNTARY ANNOUNCEMENT - PURCHASE OF SHARES BY THE TRUSTEE FOR THE PURPOSE OF THE 2022 RSU SCHEME](https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0611/2026061101513.pdf) 13. 2026-05-27 HKEXnews [DIS-APPLICATION OF RULES 18A.09 TO 18A.11 OF THE LISTING RULES AND REMOVAL OF STOCK MARKER](https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0527/2026052701109.pdf) 14. 2026-05-21 HKEXnews [VOLUNTARY ANNOUNCEMENT - ASCENTAGE PHARMA RELEASES LATEST CLINICAL DATA FROM MULTIPLE TRIALS AT ASCO 2026](https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0522/2026052200035.pdf) 15. 2026-05-21 HKEXnews [THIRD AMENDED AND RESTATED MEMORANDUM AND ARTICLES OF ASSOCIATION](https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0521/2026052101260.pdf) 16. 2026-05-20 HKEXnews [POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON MAY 20, 2026](https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0520/2026052001660.pdf) 17. 2026-04-30 HKEXnews [SUPPLEMENTAL NOTICE OF ANNUAL GENERAL MEETING](https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0430/2026043004054.pdf) 18. 2026-04-30 HKEXnews [SUPPLEMENTAL CIRCULAR - PROPOSED GRANTS UNDER THE 2022 RSU SCHEME AND POST-IPO SHARE OPTION SCHEME TO DR. YANG AND DR. ZHAI; AND SUPPLEMENTAL NOTICE OF ANNUAL GENERAL MEETING](https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0430/2026043004026.pdf) 19. 2026-04-28 HKEXnews [NOTICE OF ANNUAL GENERAL MEETING](https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0429/2026042900047.pdf) 20. 2026-04-28 HKEXnews [PROPOSED RE-ELECTION OF RETIRING DIRECTORS; PROPOSED GRANTING OF GENERAL MANDATES TO ISSUE SHARES AND REPURCHASE SHARES; PROPOSED AMENDMENTS TO THE MEMORANDUM AND ARTICLES OF ASSOCIATION AND PROPOSED ADOPTION OF THE THIRD AMENDED AND RESTATED MEMORANDUM AND ARTICLES OF ASSOCIATION; AND NOTICE OF ANNUAL GENERAL MEETING](https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0429/2026042900023.pdf) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open HKEX:6855 on TradingView](https://www.tradingview.com/symbols/HKEX-6855/). ## SEC filings and registration - **SEC name**: Ascentage Pharma Group International - **CIK**: 2023311 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: AAPG (Nasdaq) - **State or country of incorporation**: E9 - **Fiscal year ends**: December 31 - **Filer category**: Non-accelerated filer
Emerging growth company - **Business address**: 68 XINQING ROAD, SUZHOU , JIANGSU - **Phone**: 86 512 8555 7777 - **Shares outstanding**: 373,322,192 as of 2026-04-01 (20-F filed 2026-04-29) ### Recent filings (8-K and 6-K are the company's own announcements) - [6-K](https://www.sec.gov/Archives/edgar/data/2023311/000121390026111727/ea0309432-6k_ascentage.htm) filed 2026-10-22 - [6-K](https://www.sec.gov/Archives/edgar/data/2023311/000121390026111393/ea0309299-6k_ascentage.htm) filed 2026-10-21 - [6-K](https://www.sec.gov/Archives/edgar/data/2023311/000121390026109623/ea0308726-6k_ascentage.htm) filed 2026-10-15 - [6-K](https://www.sec.gov/Archives/edgar/data/2023311/000121390026104196/ea0306919-6k_ascentage.htm) filed 2026-09-29 - [6-K](https://www.sec.gov/Archives/edgar/data/2023311/000121390026100763/ea0305796-6k_ascentage.htm) filed 2026-09-17 - [6-K](https://www.sec.gov/Archives/edgar/data/2023311/000121390026091901/ea0302815-6k_ascentage.htm) filed 2026-08-20 - [6-K](https://www.sec.gov/Archives/edgar/data/2023311/000121390026088773/ea0301951-6k_ascentage.htm) filed 2026-08-13 - [6-K](https://www.sec.gov/Archives/edgar/data/2023311/000121390026085424/ea0300705-6k_ascentage.htm) filed 2026-08-05 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0002023311), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Ascentage Pharma Group International is a public biotech or pharmaceutical company listed on HKEX under the ticker 6855, recorded under China. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Ascentage Pharma Group International - **Ticker**: 6855 - **Listing**: HKEX - **Country or territory**: China - **Business scope**: Pharmaceuticals: Major - **ISIN**: KYG0519B1023 - **Other listed symbols**: NASDAQ:AAPG; OTC:ASPHF - **Last quote in directory**: 2026-10-22 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/HKEX-6855/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/ascentage-pharma-international/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Ascentage Pharma Group International (6855) news: IPO", 2026-10-31, https://aibio.space/companies/ascentage-pharma-international/